Overview

Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2034-05-30

Target enrollment:

Participant gender:

Summary

This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.

Phase:

PHASE3

Details

Lead Sponsor:

Asan Medical Center

Treatments:

Paclitaxel
tislelizumab